Most patients with IBC before neoadjuvant therapy had high levels of the proangiogenic factor VEGF (median 441 pg/ml) and the pro-inflammatory cytokine IL-6 (median 9.4 pg/ml), indicating the aggressive nature of the tumor growth and its association with inflammation. Here, VEGFA is linked to inflammatory breast carcinoma.